Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.

ABSTRACT: This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).

SUBMITTER: Vu T 

PROVIDER: S-EPMC10444731 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature